Vanda Pharmaceuticals | VNDA - Assets


Vanda Pharmaceuticals reported $488.95M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.45T 44.34B Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Veracyte USD 1.44B 30.38M Mar/2026